DE69527942D1 - Modifizierte oligonukleotide - Google Patents

Modifizierte oligonukleotide

Info

Publication number
DE69527942D1
DE69527942D1 DE69527942T DE69527942T DE69527942D1 DE 69527942 D1 DE69527942 D1 DE 69527942D1 DE 69527942 T DE69527942 T DE 69527942T DE 69527942 T DE69527942 T DE 69527942T DE 69527942 D1 DE69527942 D1 DE 69527942D1
Authority
DE
Germany
Prior art keywords
pct
nucleotides
sec
modified oligonucleotides
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527942T
Other languages
English (en)
Other versions
DE69527942T2 (de
Inventor
Mesmaeker Alain De
Adrian Waldner
Jacques Lebreton
Marc-Olivier Bevierre
Catherine Lesueur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9401446A external-priority patent/GB9401446D0/en
Priority claimed from GB9412526A external-priority patent/GB9412526D0/en
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Publication of DE69527942D1 publication Critical patent/DE69527942D1/de
Application granted granted Critical
Publication of DE69527942T2 publication Critical patent/DE69527942T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69527942T 1994-01-26 1995-01-17 Modifizierte oligonukleotide Expired - Fee Related DE69527942T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9401446A GB9401446D0 (en) 1994-01-26 1994-01-26 Modified oligonucleotides
GB9412526A GB9412526D0 (en) 1994-06-22 1994-06-22 Modified oligonucleotides
PCT/EP1995/000156 WO1995020597A1 (en) 1994-01-26 1995-01-17 Modified oligonucleotides

Publications (2)

Publication Number Publication Date
DE69527942D1 true DE69527942D1 (de) 2002-10-02
DE69527942T2 DE69527942T2 (de) 2003-03-27

Family

ID=26304218

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527942T Expired - Fee Related DE69527942T2 (de) 1994-01-26 1995-01-17 Modifizierte oligonukleotide

Country Status (13)

Country Link
US (1) US6066447A (de)
EP (1) EP0741741B1 (de)
JP (1) JPH09508134A (de)
AT (1) ATE222921T1 (de)
AU (1) AU697134B2 (de)
CA (1) CA2180727A1 (de)
DE (1) DE69527942T2 (de)
DK (1) DK0741741T3 (de)
FI (1) FI116677B (de)
HU (1) HU220423B (de)
IL (1) IL112424A0 (de)
NO (1) NO316902B1 (de)
WO (1) WO1995020597A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0734433B2 (de) * 1993-12-13 2004-03-24 The Procter & Gamble Company Viskositätsstabile konzentrierte weichspülerzusammensetzungen
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1997014709A1 (en) * 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
US5808035A (en) * 1995-12-08 1998-09-15 Usher; David A. Protected nucleoside and method for its synthesis
AU3340797A (en) * 1996-06-28 1998-01-21 Novartis Ag Modified oligonucleotides
JP2002507996A (ja) * 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AR020590A1 (es) 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CA2468673C (en) 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
KR100649352B1 (ko) * 2005-04-30 2006-11-27 주식회사 하이닉스반도체 반도체소자의 제조 방법
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
KR20180030699A (ko) * 2015-07-30 2018-03-23 호리즌 오펀 엘엘씨 푸코시다제 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (de) * 1986-10-28 1990-09-19 The Johns Hopkins University Alkyl- oder Arylphosphonat-Oligonukleosid, das sich mit Nukleinesäuren vernetzen kann oder das Nukleinsäure spalten kann
WO1989008146A1 (en) * 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition of htlv-iii by exogenous oligonucleotides
DK0497875T3 (da) * 1989-10-24 2000-07-03 Gilead Sciences Inc 2'-modificerede oligonukleotider
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
HU217036B (hu) * 1990-08-03 1999-11-29 Sanofi Eljárás génexpresszió gátlására alkalmas vegyületek előállítására
CA2092002A1 (en) * 1990-09-20 1992-03-21 Mark Matteucci Modified internucleoside linkages

Also Published As

Publication number Publication date
HUT75704A (en) 1997-05-28
FI962980A (fi) 1996-07-26
IL112424A0 (en) 1995-03-30
DK0741741T3 (da) 2002-12-23
CA2180727A1 (en) 1995-08-03
FI116677B (fi) 2006-01-31
JPH09508134A (ja) 1997-08-19
NO316902B1 (no) 2004-06-21
EP0741741B1 (de) 2002-08-28
NO963092L (no) 1996-09-16
EP0741741A1 (de) 1996-11-13
DE69527942T2 (de) 2003-03-27
AU697134B2 (en) 1998-09-24
HU9602040D0 (en) 1996-09-30
AU1534795A (en) 1995-08-15
FI962980A0 (fi) 1996-07-26
NO963092D0 (no) 1996-07-24
ATE222921T1 (de) 2002-09-15
US6066447A (en) 2000-05-23
HU220423B (hu) 2002-01-28
WO1995020597A1 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
DE69527942D1 (de) Modifizierte oligonukleotide
MX9703192A (es) Nucleosidos modificados en el azucar y su uso para la sintesis de oligonucleosidos.
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK0712860T3 (da) Fremgangsmåde til oprensning og isolation af 2'-deoxy-2',2'-diflournukleosider
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
ES2061416T1 (es) Ribocimas modificadas.
FI913236A0 (fi) 9-purinylfosfonsyraderivat.
NO942327L (de)
NZ332834A (en) Glycosaminoglycan-related carbohydrate derivatives ( 5 saccharide groups ) having 4 to 6 sulphate groups
DE3671896D1 (de) Herstellung von cytosin-nukleosiden.
DK0906329T3 (da) 2'-Substituerede nukleosider og oligonukleotidderivater
DK630589D0 (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
FR2738827B1 (fr) Detection des enterobacteries
BR9801143A (pt) Copolìmeros de bloco de siloxano inovativos com espaçamento rìgidos e uso dos mesmos.
DE69323191D1 (de) Wasserlösliche retinoide
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
NO962848L (no) Monohydrat av (E)-2'-deoksy-2'-(fluormetylen)cytidin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee